Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicinova ( (MNOV) ) just unveiled an update.
On December 29, 2025, MediciNova, Inc. entered into an equity distribution agreement with Lucid Capital Markets, LLC, allowing the company to sell up to $50 million of its common stock from time to time through at-the-market offerings under Rule 415 of the Securities Act. Under the arrangement, Lucid Capital Markets will act as sales agent using commercially reasonable efforts to place shares, earning a 3.0% commission on gross proceeds, while MediciNova retains full discretion over whether, when, and at what minimum price to sell shares, and either party may suspend or terminate the program. MediciNova is not obligated to sell any shares, has agreed to indemnify the agent against certain liabilities and to reimburse specified legal expenses, and the structure provides the company with flexible, on-demand access to equity capital that can be tapped as market conditions and funding needs dictate.
The most recent analyst rating on (MNOV) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Medicinova stock, see the MNOV Stock Forecast page.
More about Medicinova
MediciNova, Inc. is a biotechnology company whose primary business involves developing and commercializing pharmaceutical products, with its equity financed through issuances of common stock to support ongoing operations and growth in the capital markets.
Average Trading Volume: 898,924
Technical Sentiment Signal: Strong Sell
Current Market Cap: $62.42M
For detailed information about MNOV stock, go to TipRanks’ Stock Analysis page.